Our Clinical Trials
GO42784 (BRE 386)
Breast CancerA Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
Lines of Therapy: AdjuvantID-VDP-103 (GI 324)
GastricStudy to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination with XELOX or Irinotecan in Patients with Advanced Gastric Cancer
Lines of Therapy: 1st Line Metastatic and Locally Advanced, 2nd Line MetastaticOP-1250-301 (BRE 416)
Breast CancerOP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-01)
Lines of Therapy: 2nd Line Metastatic, 3rd Line + MetastaticTTX-030-003 (GI 361)
Pancreatic CancerPhase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients
Lines of Therapy: 1st Line Metastatic and Locally Advanced